Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

J&J Tops 2Q Profit Forecasts

By LINDA A. JOHNSON , AP Medical Writer | July 19, 2017

With recent acquisitions and new product approvals expected to boost sales, health care products giant Johnson & Johnson has raised its financial forecasts for the year, despite a dip in second-quarter profit. The higher forecast pleased Wall Street, pushing shares up $1.51, or 1.1 percent, to $133.60 in premarket trading.

Its biggest acquisition ever, the $30 billion purchase of Swiss biopharmaceutical company Actelion, was completed on June 16, bringing J&J multiple new prescription medicines to sell. Last week, the Food and Drug Administration approved Tremfya, an injected drug for the painful skin condition psoriasis that expands the company’s key franchise of treatments for immune system disorders.

The first full quarter of sales from its acquisition of Abbott Medical Optics pushed up sales 5.1 percent for J&J’s medical devices business, which began restructuring begun a year ago to improve its results. Meanwhile, other minor acquisitions and approval of the company’s surging multiple myeloma drug to treat additional patients should also add to future revenue.

Still, higher spending on marketing, production and research pushed down Johnson & Johnson’s second-quarter profit 4.3 percent.

The maker of blood thinner Xarelto, Tylenol and other pain relievers, and medical devices on Tuesday reported net income of $3.83 billion, or $1.40 per share, down from $4 billion, or $1.43 per share, a year earlier.

Adjusted results, excluding one-time charges, amounted to $5 billion, or $1.83 per share, 4 cents better than Wall Street analysts expected. Revenue was $18.84 billion, just shy of analyst expectations for $18.89 billion.

“We are optimistic that the investments we are making will accelerate our sales growth in the second half of this year,” CEO Alex Gorsky said in a statement. “The Actelion acquisition establishes a new therapeutic area as well as another engine for growth.”

J&J, based in New Brunswick, New Jersey, gained Actelion’s three drugs for treating high blood pressure in the lungs, other marketed products and some experimental drugs in late-stage testing.

The company’s prescription drugs business, its largest segment, saw sales dip 0.2 percent to $8.64 billion, while sales of consumer health products such as Johnson’s baby care items edged up 1.7 percent to $3.48 billion. Meanwhile, sales of medical devices and diagnostic products climbed 4.9 percent to $6.73 billion, indicating the restructuring is turning around problems in the segment.

J&J said it now expects full-year earnings in the range of $7.12 to $7.22 per share, up from it April forecast of $7 to $7.15 per share. It forecast revenue in the range of $75.8 billion to $76.1 billion, up from $75.4 billion to $76.1 billion.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE